AIM: To compare the overall survival of anaplastic lymphoma kinase-positive non-small-cell lung cancer patients who received alectinib with those who received ceritinib. MATERIALS & METHODS: Two treatment arms (alectinib [n = 183] and ceritinib [n = 67]) were extracted from clinical trials and an electronic health record database, respectively. Propensity scores were applied to balance baseline characteristics. Kaplan-Meier and multivariate Cox regression were conducted. RESULTS: After propensity score adjustment, baseline characteristics were balanced. Alectinib had a prolonged median overall survival (alectinib = 24.3 months and ceritinib = 15.6 months) and lower risk of death (hazard ratio: 0.65; 95% CI: 0.48-0.88). CONCLUSION: Alectinib was associated with prolonged overall survival versus ceritinib, which is consistent with efficacy evidence from clinical trials.
AIM: To compare the overall survival of anaplastic lymphoma kinase-positive non-small-cell lung cancerpatients who received alectinib with those who received ceritinib. MATERIALS & METHODS: Two treatment arms (alectinib [n = 183] and ceritinib [n = 67]) were extracted from clinical trials and an electronic health record database, respectively. Propensity scores were applied to balance baseline characteristics. Kaplan-Meier and multivariate Cox regression were conducted. RESULTS: After propensity score adjustment, baseline characteristics were balanced. Alectinib had a prolonged median overall survival (alectinib = 24.3 months and ceritinib = 15.6 months) and lower risk of death (hazard ratio: 0.65; 95% CI: 0.48-0.88). CONCLUSION:Alectinib was associated with prolonged overall survival versus ceritinib, which is consistent with efficacy evidence from clinical trials.
Authors: Gillis Carrigan; Samuel Whipple; William B Capra; Michael D Taylor; Jeffrey S Brown; Michael Lu; Brandon Arnieri; Ryan Copping; Kenneth J Rothman Journal: Clin Pharmacol Ther Date: 2019-10-11 Impact factor: 6.875
Authors: Margaret von Mehren; Michael C Heinrich; Hongliang Shi; Sergio Iannazzo; Raymond Mankoski; Saša Dimitrijević; Gerard Hoehn; Silvia Chiroli; Suzanne George Journal: BMC Cancer Date: 2021-03-19 Impact factor: 4.430
Authors: Darren S Thomas; Aaron Y Lee; Philipp L Müller; Roy Schwartz; Abraham Olvera-Barrios; Alasdair N Warwick; Praven J Patel; Tjebo F C Heeren; Catherine Egan; Paul Taylor; Adnan Tufail Journal: Clin Transl Sci Date: 2021-03-02 Impact factor: 4.689
Authors: Ian Chau; Dung T Le; Patrick A Ott; Beata Korytowsky; Hannah Le; T Kim Le; Ying Zhang; Teresa Sanchez; Gregory A Maglinte; Melissa Laurie; Pranav Abraham; Dhiren Patel; Tong Shangguan Journal: Gastric Cancer Date: 2019-09-23 Impact factor: 7.370